Blog | BioInformant

Cynata Files for New Patent for Oncology Applications

April 12, 2017 By Cade Hildreth, Founder & President Leave a Comment

• Further patent application filed for oncology applications

• Patents strengthen the Company’s intellectual property and solidifies its focus in the field of oncology

• Patent filing forms a key part of the Company’s strategy to protect its platform

Cell Line Models & Media for Difficult to Culture Tumor Types

April 4, 2017 By Cade Hildreth, Founder & President Leave a Comment

AMSBIO has introduced a new range of cancer cell line models and culture media for the most difficult to culture tumor types where no models may exist.

Alex Sim, Managing Director at AMSBIO said, “Our new partnership with Cellaria Biosciences expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision medicine.” [Read more…]

Cynata Ramping Up Asthma Program

April 4, 2017 By Cade Hildreth, Founder & President Leave a Comment

Late last year, Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), developed compelling data in an asthma model and is now ramping up that program.

In October 2016, Cynata announced it had received convincing data from a proof of concept study of its Cymerus™ iPSC-derived mesenchymal stem cells (MSCs) in an experimental model of asthma. Those initial results demonstrated that Cymerus™ MSCs can exert a powerful effect via improved airway hyper-responsiveness. [Read more…]

Pluristem Launches Co-CEO Structure and Appoints New CFO

March 29, 2017 By Cade Hildreth, Founder & President Leave a Comment

Yaky Yanay appointed Co-Chief Executive Officer to serve together with Co-Chief Executive Officer Zami Aberman
Erez Egozi appointed as Chief Financial Officer

[Read more…]

Cynata Therapeutics Lands Japanese Giant Fujifilm

March 28, 2017 By Cade Hildreth, Founder & President Leave a Comment

It is not every day that an Aussie minnow lands a deal with a Japanese whale. When Fujifilm took a 9% equity stake in Cynata Therapeutics Ltd (ASX: CYP), it was a major lift for the regenerative medicine company, positioning Cynata to benefit not only from Fujifilm’s resources but also more broadly from current economic strategy within Japan.

Prime Minister of Japan, Shinzō Abe, has committed to building leadership around a new generation of regenerative medicine products involving human cells and tissues and Cynata is now perfectly positioned to take advantage of this in the world’s second largest market for healthcare products. [Read more…]